Anika Therapeutics (ANIK) Depreciation & Amortization (CF) (2010 - 2026)

Anika Therapeutics (ANIK) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) rose 17.58% year-over-year to $1.5 million; the TTM figure through Jun 2026 stood at $5.6 million (down 7.59% YoY), while the FY2025 annual figure was $5.4 million, down 21.96% from the prior year.
• Depreciation & Amortization (CF) rose to $1.5 million in Q2 2026 per ANIK's latest filing, from $1.4 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.9 million in Q3 2024 and bottomed at $1.3 million in Q2 2025.
• Historically, Depreciation & Amortization (CF) has averaged $1.6 million across 5 years, with a median of $1.6 million in 2023.
• Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) decreased 26.01% — and 2026, when it gained 17.58%.
• Anika Therapeutics' Depreciation & Amortization (CF) stood at $1.7 million in 2022, then slipped by 5.35% to $1.6 million in 2023, then slipped by 4.18% to $1.6 million in 2024, then dropped by 15.51% to $1.3 million in 2025, then rose by 14.19% to $1.5 million in 2026.
• Business Quant data shows ANIK's Depreciation & Amortization (CF) at $1.5 million in Q2 2026, $1.4 million in Q1 2026, and $1.3 million in Q4 2025.